Stock DNA
Pharmaceuticals & Biotechnology
GBP 74,438 Million ()
13.00
NA
265.76%
1.08
43.25%
4.61
Revenue and Profits:
Net Sales:
7,986 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,646 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.88%
0%
-12.88%
6 Months
-12.0%
0%
-12.0%
1 Year
-20.61%
0%
-20.61%
2 Years
-8.93%
0%
-8.93%
3 Years
4.05%
0%
4.05%
4 Years
-4.5%
0%
-4.5%
5 Years
-14.67%
0%
-14.67%
GSK Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.25%
EBIT Growth (5y)
1.22%
EBIT to Interest (avg)
8.50
Debt to EBITDA (avg)
1.63
Net Debt to Equity (avg)
0.99
Sales to Capital Employed (avg)
0.82
Tax Ratio
13.89%
Dividend Payout Ratio
96.58%
Pledged Shares
0
Institutional Holding
0.13%
ROCE (avg)
24.07%
ROE (avg)
54.88%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
4.67
EV to EBIT
15.21
EV to EBITDA
8.98
EV to Capital Employed
2.90
EV to Sales
2.62
PEG Ratio
NA
Dividend Yield
280.34%
ROCE (Latest)
19.09%
ROE (Latest)
35.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 10 Foreign Institutions (0.13%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
7,986.00
7,516.00
6.25%
Operating Profit (PBDIT) excl Other Income
2,873.00
2,962.00
-3.00%
Interest
184.00
162.00
13.58%
Exceptional Items
-57.00
-92.00
38.04%
Consolidate Net Profit
1,646.00
1,772.00
-7.11%
Operating Profit Margin (Excl OI)
214.60%
284.60%
-7.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 6.25% vs -7.40% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -7.11% vs 253.69% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
31,376.00
30,328.00
3.46%
Operating Profit (PBDIT) excl Other Income
8,213.00
9,287.00
-11.56%
Interest
644.00
775.00
-16.90%
Exceptional Items
-2,469.00
-1,430.00
-72.66%
Consolidate Net Profit
2,951.00
5,308.00
-44.40%
Operating Profit Margin (Excl OI)
180.50%
230.60%
-5.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.46% vs 3.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -44.40% vs 7.86% in Dec 2023
About GSK Plc 
GSK Plc
Pharmaceuticals & Biotechnology
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Company Coordinates 
Company Details
G S K House, 980 Great West Road , BRENTFORD None : TW8 9GS
Registrar Details






